Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 34c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Eagle Pharmaceuticals Reports Second Quarter 2020 Results
August 10, 2020 6:50 AM EDT-- Q2 2020 net loss was ($0.02) per basic and diluted share and adjusted non-GAAP net income was $0.59 per basic and $0.57 per diluted share --
-- Anticipate launch of vasopressin, maintaining our 180-day market exclusivity --
-- CMS establishes unique J-code for PEMFEXY (pemetrexed for injection); FDA granted supplement approval for 500mg multiple-dose vial --
-- Received positive additional data for the Companys fulvestrant product candidate, EA-114, for HR-positive advanced breast cancer --
-- Received a Complete Response Letter for NDA for... More
